Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
NCT ID NCT07705412
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study looks back at medical records of people with esophageal squamous cell carcinoma who had immunotherapy and chemotherapy before surgery, followed by complete tumor removal. The goal is to see if adding radiotherapy after surgery, and how many lymph nodes were removed, affects whether the cancer returns in the same area. Researchers will compare outcomes among patients who did or did not receive postoperative radiotherapy, based on what happened during their routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- postoperative radiotherapy and lymph node dissection
- What this could lead to
- If the results show a clear benefit, it could help doctors decide which patients with esophageal cancer should receive radiotherapy after surgery to lower the chance of cancer coming back.
- What could go wrong
- Because this is an observational study looking back at medical records, it cannot prove cause and effect. Differences in outcomes might be due to other factors, not just the treatments received.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji hospital, Wuhan, Hubei 430030
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Blood and tissue markers could forecast esophageal cancer return
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Could smarter surgery spare lymph nodes in esophageal cancer?
- Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer